Karyopharm Therapeutics | KPTI - Current Liabilities


Karyopharm Therapeutics reported $92.06M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Abbott USD 18.38B 1.88B Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Takeda JPY 2.43T 180.65B Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
TG Therapeutics USD 187.11M 33.35M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026